The use of genetically engineered mice (GEM) have been critical in understanding disease states such as cancer, and none more so than acute myelogenous leukaemia (AML), a disease characterized by over 100 distinct chromosomal translocations. A substantial proportion of cases exhibiting recurrent reciprocal translocations at diagnosis, such as t(8;21) or t(15;17) have been exhaustively studied and are currently employed in clinical diagnosis. However, a definitive conclusion regarding the leukaemogenic potential of defined transgenes for this disease remains elusive. While it is increasingly apparent that a number of cooperating mutations are necessary to develop a leukaemic phenotype, the number of models reflecting these synergisms remains few. Furthermore, little emphasis has been paid to the effect of chromosomal translocations other than recurrent genetic abnormalities, with no models reflecting the multiple abnormalities observed in high-risk cases of AML accounting for 8-10% of adult AML. Here we review the differing technologies employed in generation of GEM of AML. We discuss the relevance of GEM AML from embryonic stem cell-mediated (for example retinoic acid receptor-a fusions and AML1/ETO) models; through to the valuable retroviral-mediated gene transfer models. The latter have been used to great effect in defining the transforming properties of chromosomal translocation products such as MLL (found in 5-6% of all AML cases) and NUP98 (denoting poor prognosis in therapy-related disease) and particularly when co-transduced with bad prognostic factors such as Flt3 mutations. Finally, we comment on the emergence of newer transduction technologies, which can regulate the level of expression to defined cell lineages in both primary murine and human xenografts, and discuss how combining multiple genetic modalities, more relevant models of this complex disease are being generated.
Introduction
The generation of relevant syngeneic, transplantable and viral pre-clinical animal models of acute myelogenous leukaemia (AML) (McCormack et al., 2005) has served as invaluable tools towards our fundamental understanding of the biology of AML disease states and in the evaluation of preliminary therapeutics. However, AML is a heterogeneous disorder, in which non-random, somatically acquired chromosomal abnormalities are the most commonly observed genetic irregularities (of which the general clinical and biological details are summarized in Table 1 ). AML-associated chromosomal alterations are often classified based on their prognostic impact that is the risk of primary chemoresistance or leukaemia relapse following intensive chemotherapy. Accordingly, high-risk abnormalities are associated with low long-term disease-free survival. This clinical basis for classification of the most common abnormalities is included in Table 1 , but it should be emphasized that prognostic impact is unknown for many uncommon abnormalities. Thus, the study of AML requires the creation of more specific models, which accurately reflect this disease's multiplicity. Indeed, over 100 discrete chromosomal aberrations have been characterized reflecting both the wide patient-to-patient and disease heterogeneity observed in AML (Mrozek et al., 2001 (Mrozek et al., , 2004 . Subsequently, distinct translocations have been linked to individual subtypes of leukaemia and are associated with particular stages of disease pathogenesis (Bullinger et al., 2004; Valk et al., 2004) or prognostic outcomes (Grimwade et al., 1998; Wheatley et al., 1999) . However, definition of their exact physiological function without relevant models remains elusive. Thus, the use of well-designed genetically engineered mice (GEM) models that accurately mimic the genetic and biological progression of their equivalent human diseases facilitates the unravelling of chromosomal translocation function.
It is hardly surprising that a vast array of mouse genetic strategies have been employed to not only determine the molecular significance of these chromosomal aberrations, but to clarify the biological consequences upon AML disease states. While, an enormous body of literature exists on GEM models of AML, we wanted to compile and compare the various strategies adopted and the clinical relevance of these generated models. Therefore, the purpose of this review is to define and initially summarize the differing genetic strategies employed in the generation of GEM models of AML. Second, to catalogue and critically discuss the differing roles of chromosome translocation products and oncogenes observed in distinct prognostic subclasses of AML through the use of these models. Finally, we discuss the clinical relevance of these models and the future potential of this field in pre-clinical development of novel therapeutic strategies for this particularly lethal disease.
Generation of genetically modified mice: summary of techniques

Transgenic mice
Transgenic mice have been used in the production of several models of reciprocal translocations observed in AML, which result in fusion of two transcription factors critical to, among other functions, normal haematopoiesis. Transgenic mice may be created 'classically' through (1) direct pro-nuclear injection of exogenous DNA into fertilized zygotes (Gordon and Ruddle, 1983; Brinster et al., 1985; Palmiter and Brinster, 1986) , implantation into a pseudo-pregnant female-generating transgenic progeny or (2) via injection of genetically modified mouse embryonic stem (ES) cells into a blastocyst (Doetschman et al., 1985; Gossler et al., 1986; Robertson et al., 1986 ) (embryonic day 4.5) with (3) embryonic retroviral infection (Jaenisch, 1980; Jaenisch et al., 1981; Soriano and Jaenisch, 1986) , representing a further alternative. While direct pronuclear injection of exogenous DNA results in indiscriminate integration into the genome and is reliant upon overexpression of the transgene to generate a phenotype, ES cells can be genetically tailored via homologous recombination (Smithies et al., 1985) (that is location and enzymatic recombination of an exogenous DNA fragment into the homologous endogenous sequence; Figure 1a and Supplementary Information) in vitro prior to blastocoel insertion, representing the superior technique. Following electroporation of exogenous DNA into the ES cell and culture, selected cells containing the targeted allele are subsequently injected into blastocysts and implanted into pseudo-pregnant mothers ( Figure 1b and Supplementary Information). Chimeric male progeny (founders) are then backcrossed with wild-type mice generating F1 heterozygotes, which can be inter-crossed to generate mice homozygously transgenic of the targeted allele, in Mendelian fashion.
Knockout and knock-in mice
The most common genetic experimental approach is to ablate ('knockout') the function of the target gene by (Mrozek et al., 2004) .
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E McCormack et al Figure 1 Homologous recombination. (a) In this example, the wild-type locus, with five exons (yellow-navy), recombines with the targeting construct, which consists of a core region enclosing the desired genetic change together with a positive selection cassette (black exon: conferring neomycin resistance). The core region is bordered by two regions of absolute sequence homology with the targeted region (green and orange) obligatory for homologous recombination to occur. However, homologous recombination in embryonic stem (ES) cells is comparatively rare, with random DNA integrations prevailing. By placing a negative selection marker (For example, tk HSV thymidine kinase gene from herpes simplex virus: blue) outside the homology region of the targeting construct one can select against randomly integrated clones. The viral thymidine kinase can convert the nucleotide analogue ganciclovir into the monophosphate form; which in turn is modified to the triphosphate which inhibits cellular replication in ES cells. Therefore, only those cells carrying the tk HSV gene, For example, those, which contain non-homologous insertions, are sensitive to cytotoxic ganciclovir. Thus, recombinant cells are selected by treatment with neomycin followed by ganciclovir. P, promoter; pA, polyadenylation signal. (b) Subsequently, the homologously recombined ES cells are (i) injected into the blastocoel cavity of 4.5 day embryos, which in turn is transferred to the pseudo-pregnant mother. As the ES cells contribute to all tissues, chimeric mice are generated which are backcrossed with wild-type mice. (ii) Resultant F1 heterozygotes can then be crossed to generate (iii) homozygous mice for the disrupted allele.
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substituting it with an altered or nonsense gene. While appearing relatively simple in theory, there are several practical drawbacks in using this technique. Random integration of viral oncogenes results in both variable tissue expression level and specificity, accruing in generation of numerous transgenic lines. Subsequent determination of a line of interest is an often timeconsuming and tedious process with no guarantee of success. Generation of knock-in mice involves the targeting of mutated exogenous cDNA in-frame directly to a pre-defined locus by homologous recombination in the ES cells.
Retroviral transduction and transplantation
As murine bone marrow cells are readily available for in vitro exploitation, significant efforts have focussed on transfer of AML disease genes into murine haematopoietic cells. General studies of gene transfer into the haematopoietic stem cells (HSCs) employ an ex vivo approach in which designated genes must be transduced effectively and with high efficiency to the target cells in vitro, which in turn must survive and engraft into the marrow niches following transplantation into autologous or syngeneic recipients (Figure 2 and Supplementary Information). Such systems circumvent the issue of embryonic lethality observed in some traditional transgenic approaches allowing targeting of human oncogenes into haematopoietic stem and progenitor cells and subsequently development of several chimeric AML models. With the advent of sufficiently immunodeficient mice such as non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice, which allow xenograft of primary human haematopoietic cells and stem cells, investigators can now transduce such cells with genes implicated in leukaemogenesis, providing more relevant models. The subsequent generation of further immunocompromised NOD/SCIDs, namely the b2 microglobulin knockout NOD/SCID (NOD/SCID/ B2m null with reduced natural killer cell activity and lack of major histocompatibility complex class I (Christianson et al., 1997)) and more recently NOD/SCID mice harbouring complete null mutation of gc (the NOD/ SCID/IL2rg null strain (Ishikawa et al., 2005) ) in order to block the signalling through gc-related cytokine receptors for many lymphoid-related cytokines (for example interleukin (IL)-2, -7, -12, -15 and -21), allow superior engraftment of human populations and in particular stem cell populations.
Transgenic models
Transgenic models of acute promyelocytic leukaemia By far the most extensive work in this area has been targeted towards models of acute promyelocytic leukaemia (APL) FAB M3 accounting for 7-10% of human AML, particularly those involving translocations of chromosome 17 and gene fusions of the retinoic acid receptor-a (RARa) ( Table 2 ). The APL variant of human AML is characterized by a differentiation block leading to an accumulation of promyelocytes, coagulation abnormalities, chromosomal translocations (Grisolano et al., 1997) , PLZF/RARa t(11;17) (He et al., 1998; Cheng et al., 1999) , nucleolar phosphoprotein NPM/RARa t(5;17) (Cheng et al., 1999) , nuclear mitotic apparatus protein NuMA/RARa t(11;17)(q13;q21) (Sukhai et al., 2004) and Cyclin A1 (Liao et al., 2001) were generated with expression of exogenous cDNA directed exclusively to the myeloid compartment under regulation of human-specific promoter sequences. In particular, the human cathepsin-G (hCG) (Grisolano et al., 1994) , MRP8 (Brown et al., 1997) and CD11b (Early et al., 1996) promoters were employed resulting in explicit expression of cDNA in a number of myeloid compartments, and varying disease phenotypes. Transgenic mice with NPM/RARa (Cheng et al., 1999) , PML/RARa, PLZF/RARa and NuMa/RARa targeted to the promyelocytic compartment by the hCG vector exhibited diverse inter-and intra-specific phenotypes. The hCG-PML/RARa model mimicked the human APL phenotype as distinguished by promyelocytic accumulation in the bone marrow, extensive infiltration of leukaemic blasts preceded by protracted myeloproliferative disorders and exhibited complete, although transient, remission upon retinoic acid administration (Brown et al., 1997; Grisolano et al., 1997; He et al., 1997) . However, the hCG-NuMa/RARa and NPM/RARa models exhibited several notable differences. While, the hCG-NPM/RARa model displayed characteristics from APL to chronic myelogenous leukaemia (CML) that is further differentiation of the leukaemic cells beyond the promyelocyte stage, the hCG-NuMa/RARa model, in contrast, resulted in initial myeloproliferation of the granulocytic lineage-rapid development of myeloproliferative leukaemia with subsequent neutrophilic differentiation block, observed with complete penetrance from this single mutation. The model phenotype was indistinguishable from its human APL phenotypical equivalent and was singularly sufficient for disease development and progression (Sukhai et al., 2004) . PML/RARa was also regulated under hMRP8; expressed in early progenitors and mature cells of myeloid origin, and CD11b promoters, directing expression to myeloid-monocytic and more differentiated granulocytic compartments, in further transgenic models. Although, analogous to the hCG-PML/RARa phenotype in its response to retinoic acid treatment, the hMRP8-PML/RARa transgenic did not exhibit a terminal differentiation block in granulopoesis, while the CD11b-PML/RARa model failed to develop leukaemia, highlighting the importance of target cellular gene expression. In conclusion, the leukaemogenic potential of APL transgenes cannot be absolutely defined due to possible random integrations of cDNA, the differences in the genetic background of the GEMs and the relative doses of transgene expressed within targeted cell lineages. However, one could postulate on the evidence presented that in general APL transcription factors (1) require secondary mutations to cause APL as evidenced by the long latency of disease and (2) the cell lineage within which they are expressed is critical to disease phenotype as observed in hCG-, hMRP8-and CD11b t(15;17)-directed models (Zhu et al., 2007) (Table 2) .
Generally patients of the APL t(15;17) phenotype represent a unique group characterized by distinct biological features and good prognosis, particularly when all-trans retinoic acid (ATRA) is employed as part of remission induction (Sanz et al., 2005) . The notable exception is the APL-like AML, with PLZF/RARa t(11;17), which does not respond to ATRA therapy and results in poor prognosis and survival. Subsequent treatments of the aforementioned models lead to either differentiation or at least partial remission upon ATRA Incidence in human acute promyelocytic leukaemia (APL).
Genetic models of AML E McCormack et al administration ( Table 2 ). The hCG-PLZF/RARa model, although similar in phenotype to the PML/RARa model, demonstrated a diminished differentiation block and was more comparative to CML. However, most notable was that while ATRA could prolong survival in these animals, remission was never achieved, as observed in the human disease equivalent. The overexpression of Cyclin A1, normally only at low levels in normal human haematopoietic cells, has been found to be predominant in haematological malignancies, such as AML and particularly in patients with APL (Yang et al., 1999) . Thus, expression of Cyclin A1 under control of the hCG promoter in transgenic mice was examined (Liao et al., 2001) . Subsequent transgenic mice developed myeloproliferative disorders, which developed to AML in 15% of cases with long latency. Results suggest that Cyclin A1 is an oncogene in AML but, as observed with APL models, required further synergistic mutations.
Transgenic models of AML1/ETO
The t(8;21) variant of human AML is characterized by myelomonocytic differentiation, increased eosinophils in leukaemic marrow and good prognosis when treated with high-dose cytarabine. AML transgenic models of t(8;21) included models of hMRP8-AML1/ETO t(8;21)(q22;q22) (Yuan et al., 2001) , and more recently by directing the AML1/ETO oncogene into the stem cell compartment via targeted insertion of oncogenic cDNA into the Ly-6A locus that encodes the well-characterized HSC marker Sca1. Subsequent transgene expression was significantly lower than expected in the lymphoid compartment, suggesting that this phenotype was consequent of dominant inhibition by AML1/ETO, and a possible target for therapeutic intervention. However, the hMRP8-AML1/ETO transgenic mice were healthy for their lifespans and only developed AML upon treatment with the DNA alkylating agent N-ethyl-N-nitrosourea (ENU). ENU is a powerful mouse mutagen and inflicts point mutations resulting in single base changes defining single gene function and subsequent protein product. Similarly, DNA alkylating agents are known to induce secondary, therapy-associated AML in humans. Thus treatment of transgenic models with ENU illustrates human susceptibility for leukaemogenesis following treatment with alkylating agents. Furthermore, all wild-type littermates developed acute T-lymphoblastic leukaemia, highlighting the importance of AML1/ETO as an AML oncogene.
Other transgenic models of AML Transgenic models of fusion products, such as those mentioned above and in Table 2 reflect the more commonly observed reciprocal translocations observed in AML. However, there are a number of other poor prognostic factors highly prevalent in human AML (Grimwade et al., 1998; Bullinger et al., 2004; Marcucci et al., 2007) . These comprise mutations in tyrosine kinases such as activating FMS-like tyrosine kinase 3 (FLT3) ( (Stirewalt and Radich, 2003) and oncogenic ras mutations, including K-ras mutations prevalent in 10-15% of AML cases (Chan and Gilliland, 2004) . Further models have also been developed of transcription factors. Among these the HOX family members (known to regulate haematopoietic cell proliferation and differentiation) have been implicated in the development of AML, most notably Hoxa9 (Thorsteinsdottir et al., 2002) in addition to cyclic AMP (cAMP) response element-binding protein (CREB) overexpressed in blast cells from patients with AML, which confers survival and growth advantages to the cells (Shankar et al., 2005) .
A transgenic model harbouring a human FLT3 internal tandem duplication (ITD) mutation under expression of the vav promoter, which drives expression in the entire haematopoietic system, resulted in vav-FLT3-ITD transgenic mice. Of the founder lines generated, most developed a myeloproliferative disorder, reminiscent of the human myeloproliferative disease essential thrombocythemia (that is normal myeloid differentiation, increased megakaryocytes, high peripheral blood platelet counts) with high penetrance but long latency of between 6 and 12 months. Interestingly, two further transgenic lines developed clonal immature B-or T-lymphoid disease, reflected in the human condition T-cell ALL and CML in mixed lymphoid blast crisis where FLT3 mutations are also observed signifying that genetic background is important for disease phenotype.
Conditional transgenic models of K-ras developed a lethal myeloproliferative disease with complete penetrance, utilizing Cre recombinase under control of interferon a/b inducible MX promoter. Furthermore, a transgenic model directing overexpression of Hoxa9 to lymphoid cells exhibited an increase of approximately 15-fold in lymphomyeloid, long-term repopulating cells. Similar increases were also observed in a chimeric model (in which bone marrow cells from a donor mouse were transduced and administered to a syngeneic recipient), suggesting that Hoxa9 was a regulator of HSC expansion. While these results suggest that these mutations are certainly involved in oncogenesis, the latency of the myeloproliferative disease suggests secondary mutations. This is also true of the CREB transgenic animals (Shankar et al., 2005) that also developed long latency myeloproliferative diseases. Intriguingly, cyclin A was upregulated in these animals, as it is in AML patients who also express high CREB levels. While the principal observation in these models was a high-penetrance myeloproliferative disorder without a development to overt AML, they should prove interesting models for the study of cooperating mutations in the development of AML and in the development of new Ras or FLT3 inhibitors.
Cross-breeding of transgenics
From the above work it is apparent that location of cDNA integration site is critical to the development of a disease phenotype. One can also conclude that while (Kogan et al., 2001) . Cross-breeding LSL-K-ras with cathepsin G-PML-RAR mice (Chan et al., 2006) developed APL-like disease with a penetrance of 69% and average disease latency of 39 days, with the remaining mice developing a myeloproliferative disease. These results further corroborate the general findings, discussed in the preceding sections, whereby single mutations were not sufficient to initiate a replicable AML disease state alone, but only with accrual of further synergistic genetic mutations. Additionally, they can be used to study and identify multi-step malevolent transformation from low grade to aggressive haematological malignancies.
Knockout models
However, to investigate the normal function of specific genes targeted by the t(8;21) and t(8;22) translocations in AML, knockout models of AML1 (Okuda et al., 1996) , CBFb and PML (Wang et al., 1998) were generated. While both AML1 and CBFb knockout mice resulted in embryonic death due to central nervous system haemorrhage, it was shown that AML1 À/À ES cells were unable to contribute to any haematopoietic lineage in chimeric mice. However, expression of AML1, under endogenous regulation via targeted insertion, abrogated this effect. In the PML À/À mice no leukaemia was noted, but animals were highly susceptible to carcinogen-induced disease suggesting its role in cooperation with secondary mutations. AML has clonal origins initiated by a single progenitor cell exhibiting somatically acquired translocations. However, knockout of genes, as exemplified above, carried in the murine germ line results in random integration sites, negating target gene function essential for normal embryonic development and frequently resulting in embryonic lethality, foiling potential studies. So while results suggest that the above genes are critical to support haematopoietic cell proliferation, their possible roles in leukaemogenesis cannot be investigated with this method.
Of further interest in this hierarchical disease, where the roles of tumourigenic stem cell populations are all too apparent, are the mechanisms and regulation of HSC renewal. Subsequent investigations of primitive HSC by gene array analysis identified the protooncogene Bmi-1, expressed in all AML and resulted in the creation of a knockout model (van der Lugt et al., 1994) . Bmi-1 collaborates with c-myc in the formation of mouse lymphomas and appears to contribute in cell cycle regulation and senescence by acting as a transcriptional repressor of the INK4a/ARF locus. Bmi-1 À/À mice die after less than 2 months resultant of hypocellular bone marrows and investigations by two separate groups (Lessard and Sauvageau, 2003; Park et al., 2003) revealed that there was no detectable self renewal of HSCs from bone marrow of Bmi-1 À/À mice, and Bmi-1 À/À impaired the expression of tumourigenic cyclin kinase inhibitors p19 ARF and p16
INK4a
. Furthermore, retroviral transduction of Bmi-1 À/À bone marrow cells with Hoxa9-Meis1 retrovirus and subsequent transplantation in syngeneic hosts resulted in leukaemia of similar latency as (Hoxa9-Meis1 or Bmi-1 þ / þ Hoxa9-Meis1) controls. However, implantation of derived, highly proliferative clones of Bmi-1 À/À Hoxa9-Meis1 resulted in no disease or long latency disease compared with all control Hoxa9-Meis1 mice succumbing to AML with short latency. Reintroduction of Bmi-1 to these Bmi-1 À/À Hoxa9-Meis1 clones and implantation in mice resulted in AML with complete penetrance and short latency. Results demonstrate that not only is Bmi-1 critical to the renewal of normal haematopoietic tumourigenic stem cells, but that Bmi-1 is also critical to the regulation of tumourigenic proteins.
Knockdown models
As described above the use of knockout models is limited to exploring gene function as most knockouts result in embryonic lethality. However, more recent publications have described the use of hypomorphic or graded 'knockdown' of disease-specific genes. Specifically, Sfp1 knockdown mice (Rosenbauer et al., 2004) , encoding a lineage-specific transcription factor PU.1, where PU.1 levels were reduced to 20%, developed AML, while homo-and heterozygous animals did not. Furthermore, conditional expression of PML/RARA suppressed PU.1 expression, while treatment with ATRA restored PU.1 levels and induced differentiation (Mueller et al., 2006) , suggesting PU.1 is suppressed in APL. This was further confirmed by the authors where conditional expression of PU.1 induced differentiation in APL cells, while reduction by small interfering RNAs blocked ATRA-induced differentiation. In a further study (Grisendi et al., 2005) in which a hypomorphic mutant series of Npm1 were generated both the knockout mice and Npm1 hy/hy resulted in embryonic lethality (although the Npm1 hy/hy embryos survived 5 days longer), while Npm1 þ /À developed a haematological syndrome similar to human myelodysplastic syndrome (MDS). Thus, it can be concluded that not only is it crucial that gene expression is delivered in the correct locus but also that the level of gene expression is critical in development of a phenotype. Further advances of these techniques may render more accurate and useful models of translocations described in human AML.
Knock-in models
As mentioned in the techniques section, in this approach the mutated exogenous cDNA is targeted in-frame directly to a pre-defined locus by homologous recombination in the ES cells and employed in developing knock-in models of the following: AML1-ETO t(8;21) (Yergeau et al., 1997; Okuda et al., 1998; Fenske et al., 2004) , PLZF-RARa t(11;17) (He et al., 1999) , CBFb-MYH11 inv(16) t(16;16) found in AML subtype FAB M4Eo (that is myelomonocytic differentiation together with increased eosinophilic progenitors) (Castilla et al., 1996) , CBFb-GFP (Kundu et al., 2002) , MLL-AF9 t(9;11) found in AML FAB M5 (that is myelomonocytic variants) (Dobson et al., 1999) and MLL-lacZ (Dobson et al., 2000) . Resultant AML-ETO or CBFb-MYH11 knock-in fusion genes resulted in embryonic lethality owing to lack of definitive embryonic haematopoiesis in a manner remarkably similar to that of the corresponding (AML1 À/À , CBFb À/À ) knockout animals. This suggested that these fusion proteins are dominant-negative inhibitors of corresponding normal gene function during primitive haematopoietic lineage commitment. In only one exception, where AML-ETO was targeted to the stem cell compartment by Ly6A locus (Fenske et al., 2004) did animals survive and developed a long (>6 months) latency myeloproliferative disease, reinforcing the idea that disease phenotype is dependent of the cellular compartment-targeted and accumulation of mutations.
Additionally, CBFb-GFP knock-in mice were found to express CBFb in stem and progenitor cells in midgestation embryos and adult mice, implying that CBFb is essential for the development of stem-progenitor cells, and CBFb-MYH11 blocks embryonic haematopoiesis at this cellular level. However, 84% of CBFb
chimeras (Castilla et al., 1999) , which do not develop leukaemia in their first year of life, died from AML FAB M4 (that is myelomonocytic variant)-type disease when administered a single dose of ENU 2-6 months after treatment. In contrast, none of the wild-type chimeras treated with ENU developed disease, concluding that CBFb-MYH11 blocks differentiation, but cooperation with further oncogenes is necessary for leukaemogenesis. Furthermore some cells exhibited nuclear characteristics of monocytes and both basophilic and eosinophilic granules in the cytoplasm, characteristic for the FAB M4Eo subtype of human AML. Conversely, an MLL-lacZ (fusion of MLL and the reporter b-galactosidase, lacZ) knock-in model resulted in ES-derived AML in some of the animals, which is very interesting as lacZ has no known oncogenic function, indicating that truncation and fusion of MLL can be sufficient alone to cause tumourigenesis, regardless of fusion partner. Additionally, mice heterozygous for MLL-AF9 developed AML with myelomonocytic differentiation comparable to human FAB M4-5. Although these results are insightful, the approach has several intrinsic disadvantages, most notably the unrestricted expression pattern of the mutated gene. Consequently, several methods were developed for conditional or inducible in vivo gene expression, the details of which are described in several noteworthy reviews (Muller, 1999; Testa and Stewart, 2000; Ryding et al., 2001; Yu and Bradley, 2001; Bockamp et al., 2002; van der Weyden et al., 2002) .
Conditional knock-in
A modification of the knock-in approach targets mutated genes into loci other than that of the involved gene and whose expression is restricted to the cell type where the aberrant gene is expressed in the human disease.
Employing this methodology a knock-in model of PML/RARa t(15;17) using the endogenous murine cathepsin G-promoter was generated with 90% incidence of APL in comparison to only 15-20% prevalence observed in the relative hCG-PML/RARa, with similar pathology (Westervelt et al., 2003) . The tetracycline (tet-) inducible (Gossen and Bujard, 1992; Gossen et al., 1995; Jaisser, 2000; Ryding et al., 2001) and Cre/loxPmediated (Muller, 1999; Jaisser, 2000; Testa and Stewart, 2000; Ryding et al., 2001; Yu and Bradley, 2001 ) interchromosomal translocation recombination systems have been utilized in generation of inducible models of AML1/ETO t(8;21) (Buchholz et al., 2000; Higuchi et al., 2002; Rhoades et al., 2000) , MLL-CBP t(11;16) , MN1-TEL t(12 ;22) (Kawagoe and Grosveld, 2005) and MLL/AF9 t(9;11) (Collins et al., 2000) . In both the tet-off and Cre-loxP models of AML1/ETO (Rhoades et al., 2000; Higuchi et al., 2002) , the transcriptional control of AML1/ETO fusion protein was highly expressed in bone marrow, however, as noted in the hMRP8-AML1/ETO model, there was no development of leukaemic phenotype unless expressed with cooperating mutations. Nevertheless, increased replating efficiencies and partial block in myeloid differentiation were perceived in vitro, intimating, in tandem with results from previously described models for this translocation, that although solitary AML1/ETO is insufficient to cause leukaemia, it blocks normal AML1 function and regulates expression of other haematopoietic genes (Rhoades et al., 2000) . Collins et al. (Collins et al., 2000) employed the Cre Thus the advantages of these systems are their ability to 'turn on' knocked-in genes to avoid embryonic lethality and study their function in mature adults, as in the human disease.
Chimeric models
As bone marrow cells and PBLs are readily available for in vitro exploitation, significant efforts have focussed on transfer of AML disease genes into both murine and human haematopoietic cells (Table 3) AML/ETO t(8;21) Retroviral transfection and transduction of AML/ETO (de Guzman et al., 2002) into an enriched HSC population resulted chimeric mice with haematopoietic abnormalities, including a significant increase in immature eosinophil myelocytes, as observed in patients with t(8;21). Conversely, mice transplanted with cells expressing only the DNA-binding domain of AML1 (de Guzman et al., 2003) exhibited normal haematopoiesis, demonstrating that the ETO-binding domain is requisite in development of AML/ETO-associated haematopoietic anomalies. Nevertheless, as with previous transgenic models expressing the AML1-ETO fusion protein (Yergeau et al., 1997; Okuda et al., 1998; Rhoades et al., 2000; Yuan et al., 2001; Higuchi et al., 2002) , no 
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Whole BM NA Aggressive AML (100%) Splenomegaly, anaemia undifferentiated myeloblasts in BM, S + PB (Rawat et al., 2004) Abbreviations: ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; APL, acute promyelocytic leukaemia ATRA, all-trans retinoic acid; BM, bone marrow; MPD, myeloproliferative disease; NA, not available; NOD/SCID, non-obese diabetic/severe combined immunodeficiency disease; PB, Peripheral blood; S, spleen; WBC, white blood cell count.
Genetic models of AML E McCormack et al primary or disseminated leukaemia was observed. Subsequently, AML/ETO t(8;21) was transduced to bone marrow derived from mice deficient of the interferon regulatory factor ICSBP (Schwieger et al., 2002) , implicated as a suppressor of myeloid neoplasia (Holtschke et al., 1996; Gabriele et al., 1999; Scheller et al., 1999) and was found to synergize with ICSBP deficiency to incite myeloblastic conditions evocative of AML. Furthermore, activating mutations in receptor tyrosine kinases, for example TEL/PDGFbR and Flt3, were found to cooperate with AML/ETO (Grisolano et al., 2003) , NUP98/HOXA9 t(7;11) (Dash et al., 2002) and PML/RARa t(15;17) (Kelly et al., 2002) causing AML (FAB M2)-type leukaemia, AML and APL, respectively in transduced mice. Concurrently, cotransduction of murine HSCs with mutated tyrosine kinase BCR/ABL and translocation of NUP98/HOXA9 resulted in AML following transplantation into syngeneic mice (Dash et al., 2002) . The disease phenotype was akin to that observed in CML patients, whose disease state had progressed to a blast crisis, following the further accumulation of secondary translocations for example NUP98/HOXA9.
MLL/ELL t(11;19) and AML1/MDS1/EVI1 t(3;21)
The technique of retroviral transduction and transplantation was also applied in the genesis of MLL/ELL t(11;19) (Lavau et al., 2000b) and AML1/MDS1/EVI1 t(3;21) (Cuenco et al., 2000) murine models, inducing disease states which recapitulated that of the equivalent human phenotype but with long disease latencies (100-200 days and 5-13 months, respectively; see Table 3 ). Transplantation of cells from MLL/ELL (Lavau et al., 2000b) and AML1/MDS1/EVI1 (Cuenco et al., 2000) leukaemic mice into secondary recipients instigated identical disease states with significantly reduced latencies (average of 43 and 40 days, respectively), thus reiterating the suggestion that translocated genes, although crucial for AML induction, obligate acquisition of further genetic abnormalities to induce advanced disease. Subsequently, co-transduction and transplantation of doubly BCR/ABL-AML1/MDS1/EVI1 (Cuenco and Ren, 2001 ), Hoxa9-Meis1 (Kroon et al., 1998) and Hoxa9-E2A/Pbx1 (Thorsteinsdottir et al., 1999) transfected cells into syngeneic recipients yielded aggressive AML diseases of short latencies (50, o90 and 39 days, respectively) in comparison to singly transduced and transplanted animals. Thus the usefulness of these models is emphasized with the ability to investigate the interactions of several disease genes simultaneously in one model, avoid the time consuming generation and phenotyping of various transgenic animals while circumventing problems such as embryonic lethality.
Therapy-related 11q23 and 11q15 translocations Translocations involving chromosome 11 are described by the World Health Organization classification of haematological malignancies as related with both de novo and therapy-related AML (predominantly topoisomerase II inhibitors; Table 4 ) (Harris et al., 2000) . In particular recurring translocations involving the 11q23 and 11q15, which encode the MLL and NUP98 genes, are of particular importance with MLL translocations found in 5-6% of all AML cases and NUP98 denoting poor prognosis in therapy-related disease. Employing retroviral transduction and transplantation, chimeric models of a number of MLL fusion partners were generated, including MLL-ENL t(11;19) (Lavau et al., 1997) , MLL-ELL t(11;19) (Lavau et al., 2000b) , MLL-AFX t(X;11) (So and Cleary, 2002) , MLL-CBP t(11;16) (Lavau et al., 2000a) and MLL-SEPT6 t(X;11) (Ono et al., 2005) . Typically, long latency diseases (>100 days) exclusively of the myelomonocytic origin were induced with all MLL fusion genes. Characteristically, recipient animals were anaemic, thrombocytopenic and displayed extensive leukaemic infiltrations of the kidney, spleen, liver, thymus and/or lymph nodes with almost complete replacement of normal bone marrow with myeloblasts and myelocytes. This is consistent with the clinical picture where patients may present with predominance of monoblasts and monocytic sarcomas and/or tissue infiltrations. Despite the relative homogeneity of pathology, there were some notable differences in the models. The MLL-ENL model had diseases of shorter latencies (48-82 days), and in a further study (Cozzio et al., 2003) where MLL-ENL was transduced into stem cells or myeloid, granulocytic or macrophage progenitors and subsequently transplanted into syngeneic recipients was found to induce identical disease states regardless of initiating cell. These results support the thesis that transient progenitors, which express the MLL oncogene, can cause AML. Co-transduction of MLL-SEPT6 (which presents with myeloproliferative disease with disease latency of 120±32 days) with FLT3-ITD resulted in myelomonocytic AML with reduced disease latency of 63 ± 18 days. Additionally, in a similar experiment with MLL-ENL co-transduced with FLT3-ITD resulted in AML with disease latency of only 17.6 ± 1.8 days, suggesting that FLT3-ITD can synergize as a secondary genotoxic event to induce AML with short latency. Finally, the MLL-CBP model exhibited a long pre-leukaemic phase reflecting the clinical picture in which this translocation is observed almost exclusively in AML or MDS resulting from topoisomerase II treatment.
Animal models of AML secondary to MDS Recipient mice of whole bone marrow transduced with the NUP98-TOP1 t(11;20) (Gurevich et al., 2004) translocation, observed in patients with therapy-related MDS and AML, developed progressive mild anaemia by 6 months and succumbed to AML with median survival of 234 days, the latency of which was reduced to 77 days upon secondary transplantation. However, in a model of t(2;11) (Pineault et al., 2003) , the gene product produced from fusion of nucleoporin NUP98 with HOXD13 (a member of the homebox family of genes and also associated with therapy-related AML/MDS) animals developed only long latency myeloproliferative disorders. Co-expression of NUP98-HOXD13 with Meis1, a HOX co-factor resulted in myeloblastic AML with all animals becoming moribund by 75 days. The results generated from these murine models of the most common genetic anomalies observed in AML appear to corroborate the theories that establishment of an aggressive AML phenotype requires the accumulation of several synergistic genetic abnormalities. Thus these models are now utilized not only in confirmation of the roles of observed oncogenic mutations in human AML, but are now some of the most powerful experimental techniques in elucidating and substantiating their role in this lethal disease.
Summary and future directions
While a large number of genetically engineered AML models have been described, it is our opinion (summarized in Table 5 ) that while the major contribution of these studies is to our understanding of leukaemogenesis as a multi-step process, the clinical relevance has been limited. These studies have confirmed that investigated oncogenes and ensuing animal disease often exhibit phenotypic similarities observed in corresponding human disease, suggesting their involvement in the development of hu-AML. While more recent studies with NOD/SCID human xenograft models of transduced CD34 þ populations (Mulloy et al., 2003; Shen et al., 2004; Warner et al., 2005) have endeavoured to elucidate oncogenic function in hu-AML development, no disease models thus far have been described. Additionally, only limited numbers of clinically defined genetic abnormalities have been investigated. Thus, it is unknown whether these observations are relevant for larger groups of patients with normal cytogenetics or uncommon cytogenetic abnormalities. In particular there are no described, specific genetic models that define high-risk groups. As discussed, there has been some progress in combining models of defined chromosomal abnormalities with bad prognostic factors such as FLT3 and RAS mutations, but none with deletions of chromosomes 5 and 7. Furthermore, the regulation of transgenes in future models must be generated with more emphasis not only in the relevant, comparative human myeloid cell lineage but also expression level, to affect more relevant models.
While the function of genetic model thus far has primarily be restricted to elucidating the molecular aspects of AML, the prospective use of these models in Abbreviations: ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; APL, acute promyelocytic leukaemia; ATRA, all-trans retinoic acid; BM, bone marrow; CMP, common myeloid progenitor; GMP, granulocyte/macrophage progenitor; HSC, haematopoietic stem cell; K, kidney; L, liver; LN, lymph node; MPD, myeloproliferative disease; NA, not available; NOD/SCID, non-obese diabetic/severe combined immunodeficiency disease; PB, peripheral blood; S, spleen; T, thymus; WBC, white blood cell count.
Genetic models of AML E McCormack et al the development of novel therapeutics or treatment regimes is exciting. Description of novel regimes developed from transgenic PML/RARA APL cells highlights their potential use. In this isolated report (Guillemin et al., 2002) retinoic acid-resistant PML/ RARA APL mice responded to a combination of RA, As 2 O 3 and cAMP phosphodiesterase inhibitor with greatly increased growth arrest and enhanced RA-or As 2 O 3 -induced differentiation. Subsequent to results generated in this mouse model, an APL patient with combined RA-As 2 O 3 resistance, treatment with combined RA, As 2 O 3 and theophylline induced blast clearance and restored normal haematopoiesis. The future use of these models in more translational approaches with novel molecular agents may reap rich rewards particularly in development of treatments towards AMLs exhibiting NPM1 (5q35) mutations, described in approximately 35% of all AML cases, and in high-risk patients as defined by the chromosomal deletion 5 and 7 groups. In generation of the models reviewed here it is common practice to mark the particular oncogene of interest with a readily definable fluorescent or luminescent protein, such as green fluorescent protein or luciferase. With the inception of highly sensitive small animal molecular imaging modalities (McCormack et al., 2007) and the increasing potential of intravital microscopy methodologies (Sipkins et al., 2005) , the use of such markers could be exploited to monitor disease development in mice, in specific anatomical compartments, spatio-temporally without necropsy. This would compliment oncogenic studies as disease development could be monitored in real-time and specific animals followed longitudinally. Finally, the use of such optical technologies monitoring the progression of disease states reviewed here may greatly aid in the efficient development of more relevant animal models of specific AML disease phenotype, but also aid the development and appraisal of novel molecular therapeutics or regimes. Allowed us a better appreciation of the molecular characteristics and implications of chromosomal abnormalities including the thesis that AML is a multi-step process requiring a number of synergistic mutations
Major drawback
Many of the models have knocked out or knocked-in gene function in particular murine compartments without assessing the effect of random integrations or expression levels of cDNA. The additional fact of genetic difference between mice and humans limits the clinical relevance of these models
Further development
In order to gain as much functional and clinically relevant data from these models further models of more diverse and uncommon cytogenetic abnormalities must be generated with controlled expression levels
Positives
As exemplified by the extensive work done on the defined APL models, these animal models can be used for the pre-clinical development of new therapeutic regimes and agents, and this can be translated into the clinical setting
Future directions
Generation of new therapeutics from clinically relevant genetic models Development of definitive models of NPM1 and more models of cooperative mutations
The use of optical imaging techniques to aid model definition and disease, and aid development of therapeutic strategies Abbreviations: AML, acute myeloid leukaemia; APL, acute promyelocytic leukaemia; NPM1, nucleophosmin.
Genetic models of AML
E McCormack et al
